Mirum Pharmaceuticals Quarterly Income Statement
NASDAQ: MIRMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mirum Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Mirum Pharmaceuticals generated $176.2 million in revenue, up 37.9% from the same quarter a year earlier. Mirum Pharmaceuticals reported a net loss of $67.2 million, compared with a loss of $5.9 million a year earlier. Operating margin was -24.1%.
Diluted earnings per share came in at -$1.06.
Summary generated from market data by MetaCap's automated system. Methodology
Mirum Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176.24M | 159.88M | 148.93M | 133.01M | 127.78M | 111.58M | 99.41M | 90.38M | 77.88M | 69.22M | 69.55M | 47.73M |
| Revenue growth (YoY) | +37.92% | +43.28% | +49.81% | +47.17% | +64.09% | +61.20% | +42.93% | +89.37% | +107.68% | +119.07% | +149.24% | +154.13% |
| Operating Expenses | 218.78M | 949.35M | 153.50M | 130.41M | 132.77M | 126.77M | 123.64M | 103.06M | 102.11M | 95.69M | 102.14M | 72.87M |
| Research & Development | 90.53M | 97.91M | 51.11M | 42.96M | 46.07M | 41.04M | 44.03M | 31.71M | 32.67M | 32.22M | 30.93M | 26.12M |
| Selling, General & Admin | 81.47M | 96.33M | 74.13M | 61.91M | 63.29M | 57.71M | 56.83M | 50.55M | 49.21M | 45.64M | 46.18M | 36.53M |
| Operating Income | -42.54M | -789.47M | -4.57M | 2.60M | -4.99M | -15.18M | -24.22M | -12.68M | -24.23M | -26.47M | -32.59M | -25.15M |
| Interest Expense | 2.62M | 3.62M | 3.60M | 3.61M | 3.59M | 3.60M | 3.58M | 3.59M | 3.57M | 3.58M | 3.56M | 3.57M |
| Other Income (Expense) | -24.23M | 0 | -218.00K | 395.00K | 86.00K | 2.11M | 231.00K | -1.09M | 312.00K | 1.76M | -3.06M | 1.32M |
| Pretax Income | -65.54M | -789.68M | -4.96M | 2.64M | -5.46M | -13.65M | -24.37M | -13.89M | -24.00M | -24.66M | -35.43M | -23.34M |
| Income Tax | 1.69M | 475.00K | 767.00K | -262.00K | 402.00K | 1.03M | -576.00K | 347.00K | 635.00K | 624.00K | 225.00K | 249.00K |
| Net Income | -67.23M | -790.15M | -5.73M | 2.90M | -5.86M | -14.68M | -23.79M | -14.23M | -24.64M | -25.28M | -35.66M | -23.59M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.06 | -13.43 | -0.11 | 0.06 | -0.12 | -0.30 | -0.49 | -0.30 | -0.52 | -0.54 | -0.69 | -0.57 |
| EPS (Diluted) | -1.06 | -13.43 | -0.10 | 0.05 | -0.12 | -0.30 | -0.49 | -0.30 | -0.52 | -0.54 | -0.69 | -0.57 |
| Shares Outstanding (Basic) | 63.37M | 58.85M | — | 50.64M | 49.73M | 48.89M | — | 47.78M | 47.24M | 46.93M | — | 41.10M |
| Shares Outstanding (Diluted) | 63.37M | 58.85M | — | 56.99M | 49.73M | 48.89M | — | 47.78M | 47.24M | 46.93M | — | 41.10M |
| EBITDA | -35.60M | -782.59M | 1.51M | 8.66M | 1.07M | -9.13M | -18.17M | -6.63M | -18.38M | -20.80M | -27.09M | -22.49M |
| Operating Margin | -24.14% | -493.78% | -3.07% | 1.96% | -3.90% | -13.61% | -24.36% | -14.03% | -31.12% | -38.24% | -46.85% | -52.69% |
| Net Margin | -38.14% | -494.21% | -3.85% | 2.18% | -4.59% | -13.15% | -23.93% | -15.75% | -31.64% | -36.52% | -51.27% | -49.42% |
This table shows 12 quarterly periods of Mirum Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow MIRM's reporting calendar. What is a income statement?